Melissa A Deadmond1,2, Julie A Smith-Gagen3,4. 1. School of Community Health Sciences, University of Nevada, Mail Stop 274, 1664 North Virginia Street, Reno, NV, 89557, USA. 2. Biology Department, Truckee Meadows Community College, Mail Stop SIER 200S, 7000 Dandini Boulevard, Reno, NV, 89512, USA. 3. School of Community Health Sciences, University of Nevada, Mail Stop 274, 1664 North Virginia Street, Reno, NV, 89557, USA. jsmithgagen@unr.edu. 4. Biology Department, Truckee Meadows Community College, Mail Stop SIER 200S, 7000 Dandini Boulevard, Reno, NV, 89512, USA. jsmithgagen@unr.edu.
Abstract
PURPOSE: Recent diagnostic and cancer reporting changes influencing myeloproliferative neoplasms (MPNs) encourage the assessment of trends and examination of the recently identified MPN subtypes: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), across the age continuum by race and ethnicity. METHODS: Surveillance, Epidemiology, and End Results data provided MPN incidence data since 1973 and MPN subtype data since 2001. Joinpoint regression estimated annual percent changes. Poisson regression estimated risk ratios. RESULTS: The 2005 JAK2 V617F discovery and the 2008 WHO diagnostic guideline for the JAK2 V617F mutation coincide with a 31 % increase in ET and a 21 % decrease in PV incidence rates. We found that younger women had a 13-33 % higher ET risk and that women under the age of 34 had a 58 % higher PMF risk, relative to men. Blacks, aged 35-49 with a higher ET risk, also had a 69 % higher PMF risk relative to whites. CONCLUSION: Demographic characteristic of ET and PMF patients may be useful for improving risk prediction and informing clinical screening and treatment strategies. Changing guidelines, new discoveries, and in-depth analysis of a large population-based study have implications for accurately identifying incident cases of MPNs, MPN subgroups, and health resource planning.
PURPOSE: Recent diagnostic and cancer reporting changes influencing myeloproliferative neoplasms (MPNs) encourage the assessment of trends and examination of the recently identified MPN subtypes: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), across the age continuum by race and ethnicity. METHODS: Surveillance, Epidemiology, and End Results data provided MPN incidence data since 1973 and MPN subtype data since 2001. Joinpoint regression estimated annual percent changes. Poisson regression estimated risk ratios. RESULTS: The 2005 JAK2 V617F discovery and the 2008 WHO diagnostic guideline for the JAK2 V617F mutation coincide with a 31 % increase in ET and a 21 % decrease in PV incidence rates. We found that younger women had a 13-33 % higher ET risk and that women under the age of 34 had a 58 % higher PMF risk, relative to men. Blacks, aged 35-49 with a higher ET risk, also had a 69 % higher PMF risk relative to whites. CONCLUSION: Demographic characteristic of ET and PMF patients may be useful for improving risk prediction and informing clinical screening and treatment strategies. Changing guidelines, new discoveries, and in-depth analysis of a large population-based study have implications for accurately identifying incident cases of MPNs, MPN subgroups, and health resource planning.
Authors: Alberto Alvarez-Larrán; Beatriz Bellosillo; Arturo Pereira; Ana Kerguelen; Juan Carlos Hernández-Boluda; Luz Martínez-Avilés; Concepción Fernández-Rodríguez; Montse Gómez; Luis Lombardía; Anna Angona; Agueda Ancochea; Alicia Senín; Raquel Longarón; Blanca Navarro; María Collado; Carlos Besses Journal: Am J Hematol Date: 2014-02-21 Impact factor: 10.047
Authors: Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross Journal: Blood Date: 2005-05-26 Impact factor: 22.113
Authors: James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield Journal: Blood Date: 2009-04-08 Impact factor: 22.113
Authors: Glen J Titmarsh; Andrew S Duncombe; Mary Frances McMullin; Michael O'Rorke; Ruben Mesa; Frank De Vocht; Sarah Horan; Lin Fritschi; Mike Clarke; Lesley A Anderson Journal: Am J Hematol Date: 2014-06 Impact factor: 10.047
Authors: M Hultcrantz; A Ravn Landtblom; B Andréasson; J Samuelsson; P W Dickman; S Y Kristinsson; M Björkholm; T M-L Andersson Journal: J Intern Med Date: 2020-01-11 Impact factor: 8.989
Authors: Andrea L C Schneider; Charles Jonassaint; A Richey Sharrett; Thomas H Mosley; Brad C Astor; Elizabeth Selvin; Josef Coresh; Rebecca F Gottesman Journal: J Gerontol A Biol Sci Med Sci Date: 2015-09-11 Impact factor: 6.053
Authors: Chris Varghese; Tracey Immanuel; Anna Ruskova; Edward Theakston; Maggie L Kalev-Zylinska Journal: Curr Oncol Date: 2021-04-18 Impact factor: 3.677